AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9876394 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing on homolateral foot
Number of subjects: 32
Study 9876394 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended knee view
Number of subjects: 32
Study 9876394 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal controls)
Number of subjects: 32
Study 9876394 — intervention group
Group type: EXPERIMENTAL
Intervention: Schuss view after 1 year
Number of subjects: 32
Study 9876394 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended knee view after 1 year
Number of subjects: 32
Study 7975698 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 448
Study 7975698 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 448
Study 2681451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg b.i.d. for three months
Number of subjects: 20
Study 2681451 — intervention group
Group type: COMPARATOR
Intervention: Placebo for three months
Number of subjects: 20
Study 2681451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin during run-out period
Number of subjects: 20
Study 2681451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin during double-blind period
Number of subjects: 20
Study 2681451 — intervention group
Group type: COMPARATOR
Intervention: Placebo during double-blind period
Number of subjects: 20
Study 2681451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin during run-out phase
Number of subjects: 20
Study 799991 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 80 mg/day
Number of subjects: 195
Study 799991 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 1600 mg/day
Number of subjects: 195
Study 799991 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen or Ibuprofen
Number of subjects: 195
Study 31150356 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoid extract 250 mg, four times a day on postoperative days 1-3
Number of subjects: 60
Study 31150356 — intervention group
Group type: COMPARATOR
Intervention: Control group (no curcuminoids)
Number of subjects: 60
Study 29224209 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month course of daily isoniazid (9H)
Number of subjects: 80
Study 29224209 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week course of weekly isoniazid and rifapentine (3HP)
Number of subjects: 80
Study 29224209 — intervention group
Group type: COMPARATOR
Intervention: 3HP (12-week course of weekly isoniazid and rifapentine)
Number of subjects: 80
Study 29224209 — intervention group
Group type: COMPARATOR
Intervention: 9H (9-month course of daily isoniazid)
Number of subjects: 80
Study 25560547 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning course on breast imaging for radiographers
Number of subjects: 107
Study 22922073 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group (VG)
Number of subjects: 213
Study 22922073 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice feedback group (VFG)
Number of subjects: 213
Study 22922073 — intervention group
Group type: COMPARATOR
Intervention: Combined group (CG)
Number of subjects: 213
Study 21125277 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 125/80 mg group (125 mg on day 1 and 80 mg on days 2-5) and dexamethasone (6 mg on day 1 and 4 mg on days 2 and 3)
Number of subjects: 20
Study 21125277 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 40/25 mg group (40 mg on day 1 and 25 mg on days 2-5) and dexamethasone (8 mg on day 1 and 6 mg on days 2 and 3)
Number of subjects: 20
Study 19275475 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidnar group (mobile narrative on a mobile phone during daily train trip)
Number of subjects: 120
Study 19275475 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonar group (only video content on a mobile phone)
Number of subjects: 120
Study 19275475 — intervention group
Group type: EXPERIMENTAL
Intervention: MP3 group (only audio content on an MP3 player)
Number of subjects: 120
Study 19275475 — intervention group
Group type: COMPARATOR
Intervention: Control group (no-intervention condition)
Number of subjects: 120
Study 16951398 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin (660 mg three times daily for three consecutive days, starting 2 days before chemotherapy)
Number of subjects: 62
Study 16951398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 16951398 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin
Number of subjects: 62
Study 12548410 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage plus fistulotomy
Number of subjects: 200
Study 12548410 — intervention group
Group type: COMPARATOR
Intervention: Drainage alone
Number of subjects: 200
Study 11460274 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet fluoride (0.25 mg F daily)
Number of subjects: 115
Study 11460274 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid fluoride (0.25 mg F daily)
Number of subjects: 115
Study 11460274 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluoride)
Number of subjects: 115
Study 9327783 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogens (0.625 mg/d)
Number of subjects: 15
Study 8269562 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine (n = 31)
Number of subjects: 120
Study 8269562 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with hyaluronidase (n = 30)
Number of subjects: 120
Study 8269562 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with epinephrine (n = 29)
Number of subjects: 120
Study 8269562 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with both epinephrine and hyaluronidase (n = 30)
Number of subjects: 120
Study 3980272 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous radiation + 5‐FU (16 patients)
Number of subjects: 30
Study 3980272 — intervention group
Group type: COMPARATOR
Intervention: Split‐course radiation + 5‐FU (14 patients)
Number of subjects: 30
Study 3980272 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance MeCCNU + 5‐FU chemotherapy (21 patients)
Number of subjects: 30
Study 3980272 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-course (12 patients)
Number of subjects: 30
Study 3980272 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-course (9 patients)
Number of subjects: 30
Study 3980272 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (30 patients)
Number of subjects: 30
Study 30420282 — intervention group
Group type: COMPARATOR
Intervention: NDCI (Non-Depressed and Cognitively Intact)
Number of subjects: 23
Study 30420282 — intervention group
Group type: EXPERIMENTAL
Intervention: LLD (Late-Life Depression)
Number of subjects: 23
Study 30420282 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI (Mild Cognitive Impairment)
Number of subjects: 23
Study 29431141 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 280
Study 27105046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy group (rosuvastatin 10 mg)
Number of subjects: 30
Study 27105046 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy group (rosuvastatin 2.5 mg)
Number of subjects: 30
Study 25513813 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth momentary assessment Routine Outcome Monitoring (mROM)
Number of subjects: 34
Study 22337533 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal hormone therapy (ever vs. never)
Number of subjects: 507
Study 20450635 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing trial (SBT)
Number of subjects: 67
Study 20450635 — intervention group
Group type: COMPARATOR
Intervention: Non-SBT (no spontaneous breathing trial)
Number of subjects: 67
Study 18539795 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (10 log(10) CFU of Lactobacillus salivarius CECT5713 and Lactobacillus gasseri CECT5714 for 4 weeks)
Number of subjects: 20
Study 18539795 — intervention group
Group type: COMPARATOR
Intervention: Control group (excipient only)
Number of subjects: 20
Study 11174502 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged antenatal betamethasone therapy (three or more sets of weekly injections given in 21.3% of cases, and > or =4 sets in 12.3% of cases)
Number of subjects: 414
Study 9886900 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Wave Analysis (PWA) for measuring Pulse Wave Velocity (PWV)
Number of subjects: 57
Study 9886900 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Wave Analysis (PWA) for measuring Augmentation Index (AIx)
Number of subjects: 57
Study 8039473 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate (FBM)
Number of subjects: 73
Study 8039473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 3180724 — intervention group
Group type: EXPERIMENTAL
Intervention: One day orientation letter
Number of subjects: 150
Study 3180724 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 3180724 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter prompt received one day before appointment
Number of subjects: 150
Study 3180724 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter prompt received three days before appointment
Number of subjects: 150
Study 3180724 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation letter received one day before appointment
Number of subjects: 150
Study 3180724 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation letter received three days before appointment
Number of subjects: 150
Study 31661946 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - treadmill walking session (5 × (3 min at 70% HRR + 3 min at 30% HRR))
Number of subjects: 15
Study 31661946 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT) - treadmill walking session (30 min at 50% HRR)
Number of subjects: 15
Study 31661946 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) - rest session
Number of subjects: 15
Study 28368456 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV immunoprophylaxis
Number of subjects: 3263
Study 28368456 — intervention group
Group type: COMPARATOR
Intervention: RSV infection
Number of subjects: 3263
Study 25596202 — intervention group
Group type: EXPERIMENTAL
Intervention: Synflorix at 2, 4, 6 months of age
Number of subjects: 425
Study 25596202 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevenar13 at 2, 4, 6 months of age
Number of subjects: 425
Study 25596202 — intervention group
Group type: EXPERIMENTAL
Intervention: Synflorix at 1, 2, 4 months plus Prevenar13 at 6 months of age
Number of subjects: 425
Study 25596202 — intervention group
Group type: COMPARATOR
Intervention: All groups (Synflorix, Prevenar13, and investigational schedule)
Number of subjects: 425
Study 23223772 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated administration of propofol and remifentanil
Number of subjects: 31
Study 23223772 — intervention group
Group type: COMPARATOR
Intervention: Manual administration of propofol and remifentanil
Number of subjects: 31
Study 21810630 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (1 mg daily dose)
Number of subjects: 69
Study 19538532 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 179
Study 19538532 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 179
Study 19538532 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 179
Study 16896862 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet CPAP
Number of subjects: 17
Study 16896862 — intervention group
Group type: COMPARATOR
Intervention: IFD CPAP
Number of subjects: 17
Study 15303780 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate shampoo 0.05%
Number of subjects: 142
Study 15303780 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 142
Study 11433556 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based data entry system for recording project activity
Number of subjects: 0
Study 11433556 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic information systems (GISs) for developing visual maps of project targets
Number of subjects: 0
Study 9282827 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (15 microM)
Number of subjects: 16
Study 9282827 — intervention group
Group type: COMPARATOR
Intervention: Control group (no zinc supplementation)
Number of subjects: 16
Study 8054933 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Number of subjects: 60
Study 8054933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30295516 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive Function Enhancement Program (EFEP) applied three times a week for six weeks
Number of subjects: 111
Study 30295516 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 111
Study 30339954 — intervention group
Group type: EXPERIMENTAL
Intervention: Restraint use
Number of subjects: 6397
Study 28543183 — intervention group
Group type: EXPERIMENTAL
Intervention: YH4808 (≥200 mg/d)
Number of subjects: 123
Study 28543183 — intervention group
Group type: EXPERIMENTAL
Intervention: YH4808 (twice-daily regimen)
Number of subjects: 123
Study 28543183 — intervention group
Group type: EXPERIMENTAL
Intervention: YH4808
Number of subjects: 123
Study 28543183 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole (40 mg)
Number of subjects: 123
Study 28543183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 25287702 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided group (38 patients)
Number of subjects: 80
Study 25287702 — intervention group
Group type: COMPARATOR
Intervention: Non-IVUS group (42 patients)
Number of subjects: 80
Study 23261366 — intervention group
Group type: EXPERIMENTAL
Intervention: Imunoglukan P4H® syrup (with pleuran-β-glucan from Pleurotus ostreatus and vitamin C)
Number of subjects: 175
Study 23261366 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin C only)
Number of subjects: 175
Study 23261366 — intervention group
Group type: EXPERIMENTAL
Intervention: Imunoglukan P4H® syrup
Number of subjects: 175
Study 21593010 — intervention group
Group type: EXPERIMENTAL
Intervention: TCARE® protocol
Number of subjects: 97
Study 21593010 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study 19258951 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/paclitaxel or carboplatin/paclitaxel (first-line chemotherapy)
Number of subjects: 783
Study 19258951 — intervention group
Group type: EXPERIMENTAL
Intervention: Her‐2/neu overexpression (2+/3+)
Number of subjects: 783
Study 16293352 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761 (120 mg/day as a single dose)
Number of subjects: 26
Study 16293352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 15462105 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg daily for 4 weeks
Number of subjects: 46
Study 15462105 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 46
Study 11737509 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.04% PHMB mouthrinse (A)
Number of subjects: 16
Study 11737509 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine aqueous solution (C)
Number of subjects: 16
Study 11737509 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available mouthrinse (Skinsept mucosa) diluted to 0.12% chlorhexidine (D)
Number of subjects: 16
Study 11737509 — intervention group
Group type: COMPARATOR
Intervention: Negative control placebo rinse (10% ethanol, flavour) (B)
Number of subjects: 16
Study 9240726 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) or HRT and parathyroid hormone peptide 1-38
Number of subjects: 19
Study 9240726 — intervention group
Group type: EXPERIMENTAL
Intervention: Dpd (deoxypyridinoline)
Number of subjects: 19
Study 9240726 — intervention group
Group type: EXPERIMENTAL
Intervention: Dpd
Number of subjects: 19
Study 9240726 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyproline
Number of subjects: 19
Study 8326078 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 126
Study 8326078 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 126
Study 8326078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 3717020 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous heparin to maintain the whole blood clotting time between 15 and 20 minutes, and commenced warfarin therapy within 48 hours.
Number of subjects: 82
Study 3717020 — intervention group
Group type: COMPARATOR
Intervention: Low-dose subcutaneous heparin and warfarin therapy if the peak creatine kinase level was more than 1,000 U/liter.
Number of subjects: 82
Study 31628019 — intervention group
Group type: EXPERIMENTAL
Intervention: IIS training program
Number of subjects: 0
Study 31628019 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving IIS training program)
Number of subjects: 0
Study 29573513 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology Internet-based intervention (PPI; n = 74)
Number of subjects: 122
Study 29573513 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition (WLC; n = 48)
Number of subjects: 122
Study 27560668 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal conus design implants (ICI)
Number of subjects: 39
Study 27560668 — intervention group
Group type: COMPARATOR
Intervention: External hex design implants (EXI)
Number of subjects: 39
Study 27560668 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ICI and EXI implants
Number of subjects: 39
Study 24354839 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders (5 weekly messages and 2 appointment reminders)
Number of subjects: 1187
Study 22348921 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP plus HereToHelp™ (HTH) patient support program
Number of subjects: 1426
Study 22348921 — intervention group
Group type: COMPARATOR
Intervention: BUP alone (standard care)
Number of subjects: 1426
Study 22348921 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliant patients (BUP + HTH)
Number of subjects: 1426
Study 22348921 — intervention group
Group type: COMPARATOR
Intervention: Non-compliant patients (BUP)
Number of subjects: 1426
Study 20590606 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 10
Study 20590606 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 10
Study 18380893 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and docetaxel (ddAT) chemotherapy with tamoxifen
Number of subjects: 248
Study 18380893 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and docetaxel (ddAT) chemotherapy without tamoxifen
Number of subjects: 248
Study 18380893 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 248
Study 18380893 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 248
Study 16644314 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 1993
Study 16644314 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg
Number of subjects: 1993
Study 16644314 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 1993
Study 14768513 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane-based anesthesia
Number of subjects: 107
Study 10713563 — intervention group
Group type: EXPERIMENTAL
Intervention: PEO/PBT 70/30 (degradable implants)
Number of subjects: 7
Study 10713563 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated defect)
Number of subjects: 7
Study 9121826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor task
Number of subjects: 0
Study 9121826 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm ischemia task
Number of subjects: 0
Study 2003657 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg labetalol
Number of subjects: 36
Study 2003657 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg labetalol
Number of subjects: 36
Study 2003657 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg labetalol
Number of subjects: 36
Study 6361759 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic 4L plasma exchange therapy with albumin replacement
Number of subjects: 39
Study 6361759 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic 4L plasma exchange therapy with plasma replacement
Number of subjects: 39
Study 6361759 — intervention group
Group type: COMPARATOR
Intervention: Chronic 4L plasma exchange therapy
Number of subjects: 39
Study 30362445 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive suppression (ES)
Number of subjects: 66
Study 30362445 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 29700412 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding infants with their head in upright position
Number of subjects: 163
Study 29700412 — intervention group
Group type: COMPARATOR
Intervention: Feeding infants without special instructions (control group)
Number of subjects: 163
Study 26662838 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/ml (Gla‐300)
Number of subjects: 241
Study 26662838 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 U/ml (Gla‐100)
Number of subjects: 241
Study 24956862 — intervention group
Group type: EXPERIMENTAL
Intervention: Detoxifying and blood circulation activating treatment with extraction of polygonum cuspidatum and hawthorn, 1 pill po, bid (5.33 mg x kg(‐1) x d(‐1) polygonum cuspidatum extraction, 5.0 mg x kg(‐1) x d(‐1) hawthorn extraction)
Number of subjects: 64
Study 24956862 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin 20 mg po, qd (0.33 mg x kg(‐1) x d(‐1))
Number of subjects: 64
Study 22326943 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (50 mg)
Number of subjects: 27
Study 22326943 — intervention group
Group type: EXPERIMENTAL
Intervention: L-theanine (100 mg)
Number of subjects: 27
Study 22326943 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of caffeine and L-theanine
Number of subjects: 27
Study 22326943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 20594555 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 193